Development of a novel equine influenza virus live-attenuated vaccine

Laura Rodriguez, Stephanie Reedy, Aitor Nogales, Pablo R. Murcia, Thomas M. Chambers, Luis Martinez-Sobrido

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


H3N8 equine influenza virus (EIV) is an important and significant respiratory pathogen of horses. EIV is enzootic in Europe and North America, mainly due to the suboptimal efficacy of current vaccines. We describe, for the first time, the generation of a temperature sensitive (ts) H3N8 EIV live-attenuated influenza vaccine (LAIV) using reverse-genetics approaches. Our EIV LAIV was attenuated (att) in vivo and able to induce, upon a single intranasal administration, protection against H3N8 EIV wild-type (WT) challenge in both a mouse model and the natural host, the horse. Notably, since our EIV LAIV was generated using reverse genetics, the vaccine can be easily updated against drifting or emerging strains of EIV using the safety backbone of our EIV LAIV as master donor virus (MDV). These results demonstrate the feasibility of implementing a novel EIV LAIV approach for the prevention and control of currently circulating H3N8 EIVs in horse populations.

Original languageEnglish
Pages (from-to)76-85
Number of pages10
StatePublished - Mar 2018

Bibliographical note

Publisher Copyright:
© 2018 Elsevier Inc.


  • Attenuated (att)
  • Equine influenza virus (EIV)
  • Influenza A virus (IAV)
  • Live-attenuated influenza vaccine (LAIV)
  • Master donor virus (MDV)
  • Reverse genetics techniques
  • Temperature sensitive (ts)

ASJC Scopus subject areas

  • Virology


Dive into the research topics of 'Development of a novel equine influenza virus live-attenuated vaccine'. Together they form a unique fingerprint.

Cite this